Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

sigma-tau is one of the most important Italian pharmaceutical groups, with a major presence also on the international stage. For more than half a century the company has been active in promoting the quality of life of man and his health. sigma-tau is present today in the most advanced research sectors, maintaining constant relations with scientific institutions with a world-wide reputation in the development of joint projects and in the implementation of original and innovative research programs. These results are the fruit of substantial, ongoing investment in research in the field of pharmaceutical innovation and stem not only from the efforts made to produce new products but also from the success of the company’s consolidated products. Bearing witness to sigma-tau’s achievements are not only the principles and values that inspire our efforts - innovation, dialogue and transparency, ethics, sustainability - but also the facts that have made sigma-tau a leading company in the research, manufacture and marketing of drugs.

Onyx Pharmaceuticals Inc. is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. In 2009, the company acquired Proteolix, Inc., a private biotechnology company. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx CEO Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.

Wilson Wolf was established in 1998 to pioneer the development of innovative mammalian cell culture devices. They have created cell culture devices for a wide variety of applications including monoclonal antibody production, living skin, corneal storage, islet transplants for type 1 diabetes, immunotherapy, and routine cell culture. Wilson Wolf is dedicated to helping scientists and businesses advance the field of healthcare through the use of their revolutionary gas-permeable cell culture device platform.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (doing business as Chia Tai Fenghai Pharmaceutical Co Ltd), a subsidiary of Sino Biopharmaceutical Ltd., is a company headquartered in Dafeng, China, that manufactures and distributes pharmaceutical products.

Part of Palette Life Sciences AB, Palette Life Sciences, Inc. is an American company located in Santa Barbara, CA, that operates as a medical device company. Per Langoe is the current CEO of the firm.\nThe company says this about itself: Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences? products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company?s portfolio of available products includes Barrigel?, Deflux?, Solesta?, and Lidbree?. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California; Dallas, Texas; Sydney, Australia; and Tokyo, Japan.

Puri Benchmark Biomedicine (Suzhou) Co., Ltd., established on 2018-09-14, Business scope includes biomedicine,R&D of medical devices,Production,Sales;biotechnology development,technical consulting,technology transfer,Technical Services;laboratory consumables,experimental reagent(Does not contain hazardous chemicals),Instrumentation(No measuring vessel),Sales of computer software, hardware and auxiliary equipment;Engage in the import and export of the above commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Carti (Shanghai) Cell Biotechnology Co., Ltd., established on 2016-03-31, Business scope includes biotechnology,Cell Medicine Technology,Medical Device Technology,Technology development in the field of laboratory equipment technology,Technical Services,technical consulting,technology transfer,Business Management Consulting,Health Management Consulting. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Part of The University of Chicago, ARCH Development Corp. is an American company. The firm provides job training and housing development services. Duane Gautier is currently the CEO of the firm.

Noastec provides consistent support activities from research and development to commercialization.

Five3 Genomics, LLC offers cancer genome data processing services. The company provides genome processing services for researchers including alignment, mutational calling, rearrangement detection, and copy number estimation. It caters to research, biotech, and patient care sectors. Five3 Genomics, LLC is based in Santa Cruz, California.

Beijing Pukang Ruiren Medical Laboratory Co., Ltd., established on 2015-11-27, Business scope includes medical laboratory services;technical consulting,technology development,Technical Services,technology transfer;Sales of laboratory instruments,Laboratory Chemical Reagents(Free of Hazardous Chemicals),Computer hardware and software and peripheral equipment(Excluding special products for computer information system security);Import and export,Technology Import and Export,Agent import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Yunbai Yao Zhengwu Technology (Shanghai) Co., Ltd., established on 2018-05-30, Business scope includes licensed projects:food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)